Raymond James has reiterated its rating on Korro Bio (Nasdaq: KRRO), citing the company's hyperammonemia outlook as the lead RNA-editing program KRRO-121 moves toward a first-in-human clinical trial in the second half of 2026.
The biopharmaceutical company, based in Cambridge, Massachusetts, uses its proprietary OPERA platform to develop oligonucleotide-promoted RNA editing therapies. KRRO-121 targets hyperammonemia driven by urea cycle disorders (UCDs) and hepatic encephalopathy, with a mechanism designed to modulate glutamine synthetase. In June, the European Medicines Agency granted Orphan Drug Designation for KRRO-121 in UCDs, a regulatory milestone that supports the upcoming clinical entry.
Second-quarter results released August 6 showed a net loss of $18.9 million, an improvement from $25.8 million a year earlier. Research and development expenses fell to $13.6 million from $20.1 million, while general and administrative costs declined to $6.5 million from $7.3 million. Cash, cash equivalents, and marketable securities stood at $137.9 million at June 30, 2026, up from $85.2 million at year-end 2025, providing a stated runway into the second half of 2028. Collaboration revenue was zero, compared with $1.5 million in the prior-year quarter, reflecting a 12-month pause in the Novo Nordisk partnership.
The pipeline expanded in May with the nomination of KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency. Preclinical data showed greater than 90% SERPINA1 RNA editing and approximately 95% reduction of the Z-AAT protein. CEO Ram Aiyar said the addition of KRRO-111 and the prospect of a third GalNAc-conjugated program this year demonstrate the platform's evolving efficiency.